The phosphoinositide-3-kinases (PI3K)/AKT and mTOR signaling pathways are currently targeted in clinical trials to treat AML by increasing cell death in combination with chemotherapy [57]. This evidence concerns the gene MTOR and acute myeloid leukemia.